EUROPEAN OPEN: SHEL LN chemicals assets draw bids; GSK LN gets priority review and Japan approval; BAYN GY sevabertinib approved in Japan; BNP FP confident in Sudan litigation; NVDA raises AI server prices by 15%+

This is a composite European open wrap rather than a single tradeable event, and the honest note is that no one line dominates: the session is being driven by a cluster of idiosyncratic corporate stories against a macro backdrop of US fiscal and sanctions headlines. On the corporate side, Shell drawing bids for US chemicals assets fits the established pattern of majors divesting downstream and chemicals exposure to concentrate on upstream cash generation; processes of this kind typically run through indicative bids to shortlisting, and the mix of strategic and financial sponsors cited is the usual one. The NVDA server price increases, if sustained, are the more consequential thread, since pricing power at the chip and system level has been the central question for the AI capex chain, and pass-through to hyperscaler customers is the transmission channel to watch. The macro overlay matters for positioning: reported Treasury buyback expansion at the long end has a record of steepening or flattening depending on whether it is read as duration support or as a symptom of issuance stress, and gold's bid alongside that narrative is the classic debasement-hedge pairing seen in past episodes of fiscal dominance concern. Sanctions headlines on Iran with China as the speculated target follow a familiar sequence: initial crude strength on supply-risk pricing, then retracement as enforcement details and exemptions emerge. The calendar, PCE, Jackson Hole and NVDA earnings, concentrates the week's event risk late, which has historically kept early-week sessions in this kind of tape rangebound and headline-driven.